Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations

Journal of Clinical Epidemiology

Volumn 59, Issue 8, 2006, Pages 808-818

  Glanz, Jason M ^a   McClure, David L ^a   Xu, Stanley ^a   Hambidge, Simon J ^a,b,c   Lee, Martin ^d   Kolczak, Margarette S ^e   Kleinman, Ken ^f   Mullooly, John P ^g   France, Eric K ^a  

^a CLINICAL RESEARCH UNIT   (United States)

^b DENVER HEALTH MEDICAL CENTER   (United States)

^c Children's Hospital Colorado   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f HARVARD PILGRIM HEALTH CARE   (United States)

^g CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

Bias (epidemiology); Case control; Cohort; Confounding factors (epidemiology); Risk interval; Self controlled case series (SCCS); Simulation study

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE;

ACUTE DISEASE; ARTICLE; CASE CONTROL STUDY; CHILD; COHORT ANALYSIS; DISEASE SIMULATION; DRUG SAFETY; HUMAN; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; MEASLES VACCINATION; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RARE DISEASE; REGRESSION ANALYSIS; RISK ASSESSMENT; SEASONAL VARIATION; STATISTICAL ANALYSIS; VACCINATION REACTION; VALIDATION STUDY;

ACUTE DISEASE; ADOLESCENT; BIAS (EPIDEMIOLOGY); CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HEALTH SERVICES RESEARCH; HUMANS; MALE; MEASLES-MUMPS-RUBELLA VACCINE; MODELS, THEORETICAL; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; TIME FACTORS;

EID: 33745699070     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2005.11.012     Document Type: Article

References (30)

1. Black C., Kaye J., and Jick H. MMR vaccine and idiopathic thrombocytopenic purpura. J Clin Pharmacol 55 (2003) 107-111
2. Miller E., Waight P., Farrington C.P., et al. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 84 3 (2001) 227-229
3. Szklo M., and Nieto M. Basic study designs in analytical epidemiology. In: Szklo M., and Nieto M. (Eds). Epidemiology: Beyond the basics (2000), Aspen Publishers, Inc, Gaithersburg, MD 3-52
4. Rothman K., and Greenland S. In: Rothman K., and Greenland S. (Eds). Modern epidemiology. 2nd ed. (1998), Lippincott-Raven Publishers, Philadelphia, PA 79-91
5. Fine P.E., and Chen R.T. Confounding in studies of adverse reactions to vaccines. Am J Epidemiol 136 2 (1992) 121-135
6. Destefano F., Mullooly J.P., Okoro C.A., et al. Childhood vaccinations, vaccination timing, and the risk of type I diabetes mellitus. Pediatrics 108 6 (2001) 112-117
7. Murphy T.V., Gargiullo P.M., Massoudi M.S., et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 344 8 (2001) 564-572
8. Black S., Shinefield H., Ray P., et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) project. Pediatr Infect Dis J 16 5 (1997) 500-503
9. Mullooly J.P., Pearson J., Drew L., et al. Wheezing lower respiratory disease and vaccination of full-term infants. Pharmacoepidemiol Drug Saf 11 (2002) 21-30
10. Mutsch M., Zhou W., Rhodes P., et al. Use of the inactivated intranasal influenza vaccine and the risk of bell's palsy in Switzerland. N Engl J Med 350 9 (2004) 896-903
11. Farrington P.C., Miller E., and Taylor B. MMR and autism: further evidence against a causal association. Vaccine 19 (2001) 3632-3635
12. Kramarz P., DeStefano F., Gargiullo P., et al. Does influenza exacerbate asthma? Analysis of a large cohort of children with asthma. Arch Fam Med 9 7 (2000) 617-623
13. Chen R.T. Safety of vaccines. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 3rd ed. (1999), W.B. Saunders Company, Philadelphia, PA 1144-1163
14. Farrington C.P., Nash J., and Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am. J Epidemiol 143 (1996) 1165-1173
15. Farrington C.P. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics 51 (1995) 228-235
16. Andrew N.J. Statistical assessment of the association between vaccination and rare events post-licensure. Vaccine 20 (2002) S49-S53
17. Farrington C.P. Control without separate methods: evaluation of vaccine safety using case-only methods. Vaccine 22 15-16 (2004) 2064-2070
18. Whitaker H.J., Farrington C.P., Spiessens B., and Musonda P. Tutorial in biostatistics: The self-controlled case series method. Stat Med (2006) [Epub ahead of print]
19. Chen R.T., Glasser J.W., Rhodes P.H., et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics 99 (1997) 765-773
20. Chu Y.W., Korb J., and Sakamoto K.M. Idiopathic thrombocytopenic purpura. Pediatr Rev 21 3 (2000) 95-104
21. Langholz B., and Goldstein L. Risk set sampling in epidemiologic cohort studies. Stat Sci 11 (1996) 35-53
22. Greenland S. Estimation of exposure-specific rates from sparse case-control data. J Chronic Dis 40 12 (1987) 1087-1094
23. Hosmer D.M., and Lemethow S. Interpretation of the coefficients of the logistic regression model. In: Hosmer D.M., and Lemeshow S. (Eds). Applied logistic regression. 2nd ed. (2000), John Wiley and Sons, Inc, New York 8-81
24. Kleinbaum D.G., Kupper L.L., Muller K.E., et al. Confounding and interaction in regression. In: Kleinbaum D.G., Kupper L.L., Muller K.E., et al. (Eds). Applied regression analysis and other multivariable methods. 3rd ed. (1998), Duxbury, Pacific Grove, CA 186-211
25. Pang D. A relative power table for nested matched case-control studies. Occup Environ Med 56 (1999) 67-69
26. Cologne J.B., Sharp G.B., Neriishi K., et al. Improving the efficiency of nested case-control studies of interaction by selecting controls using counter matching on exposure. Int J Epidemiol 33 3 (2004) 485-492
27. Schneeweiss S., Sturmer T., and Maclure M. Case-crossover and case-time-control designs as alternatives in Phamacoepidemiologic research. Pharmacoepidemiology and Drug Safety 3 (1997) S51-S59
28. Virtanen M., Peltola H., Paunio M., et al. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. Pediatrics 106 5 (2000) e62
29. France E.K., Glanz J.M., Xu S., et al. Safety of the inactivated influenza vaccine among children: A population based study. Arch Pediatr Adolesc Med 158 11 (2004) 1031-1035
30. King G., and Zeng L. Logistic regression in rare events data. Soc Politic Methodol 12 54 (2001) 137-163